Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Section 5: Patient Safety and Quality Assurance
5PSQ-113
REAL-LIFE EFFECTIVENESS, SAFETY AND ADHERENCE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS
5PSQ-112
RELATIONSHIP BETWEEN EFFECTIVENESS AND IMMUNE-MEDIATED TOXICITY OF IMMUNE CHECK-POINT INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER
5PSQ-111
MEDICATION ERRORS, THEIR PERCEPTION, ANALYSIS, AND PROPOSAL OF SOLUTIONS IN A PUBLIC HOSPITAL
5PSQ-110
IMPACT OF THE USE OF TRANSPARENT ADHESIVE DRESSINGS ON INFECTIONS IN PERITONEAL DIALYSIS
5PSQ-109
RANSOMWARE ATTACK ON A CYTOTOXIC PREPARATION UNIT (CPU): WHAT NOW?
5PSQ-108
COMPUTERIZED PHYSICIAN ORDER ENTRY WITH CLINICAL DECISION SUPPORT IN PREVENTING WRONG DOSE ERRORS IN PEDIATRIC MEDICATION ORDERS: A SYSTEMATIC REVIEW
5PSQ-107
SAFETY ASSESSMENT OF ERENUMAB AND GALCANEZUMAB IN CLINICAL PRACTICE
5PSQ-106
SAFETY PERCEIVED BY PROFESSIONALS AFTER THE INNOVATION OF THE MEDICATION USE CIRCUIT IN A NEONATAL INTENSIVE CARE UNIT
5PSQ-105
DEVELOPMENT OF HYPOMAGNESEMIA IN CRITICAL PATIENTS TREATED WITH ISAVUCONAZOLE
5PSQ-104
ERRORS IN ACENOCOUMAROL RECONCILIATION IN PATIENTS ADMITTED FROM THE EMERGENCY DEPARTMENT
5PSQ-103
PARENTAL UNMET NEEDS ON PAEDIATRIC DRUGS EXPRESSED IN FORUMS
5PSQ-102
SAFETY EVALUATION OF MIDLINE CATHETERS USED FOR ANTIBIOTIC THERAPY
5PSQ-101
ANALYSIS OF HIP PROSTHESES OVER A YEAR
5PSQ-100
UTILITY OF SOCIAL MEDIA AS A SOURCE OF PAEDIATRIC DRUG SAFETY, A SYSTEMATIC REVIEW
5PSQ-099
ADEQUACY OF SOTROVIMAB PRESCRIPTION IN SARS-CoV-2 INFECTION IN A UNIVERSITY HOSPITAL
Pages
« first
‹ previous
…
8
9
10
11
12
13
14
15
16
…
next ›
last »
Follow Us